The regulation and activity of interleukin-12.
Interleukin-12 (IL-12) is a key cytokine in the development of T helper type 1 (Th1) cell polarization, and its production of IL-12 is redundantly regulated. An important pro-inflammatory cytokine, IL-12 has been shown to have potent immunomodulatory, antitumor, and anti-infection activity in vitro and in vivo. Therefore, following a series of promising results from preclinical animal models experiments, researchers have begun to explore the clinical use of recombinant human IL-12 (rhIL-12) for treating a variety of diseases. In a series of phase I and phase II clinical trials related to cancer, viral infections, and hematopoietic stem cell transplants (HSCT), various strategies of rhIL-12 administration have been used with promising preliminary clinical results associated with tolerable toxicities.
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
Ying
Y
Wang
Kimberly T
KT
Fan
Jian-Ming
JM
Li
Edmund K
EK
Waller
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D018664:Interleukin-12 / Q000009:adverse effects / Q000378:metabolism* / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D011994:Recombinant Proteins / Q000627:therapeutic use; D014777:Virus Diseases / Q000188:drug therapy / Q000378:metabolism
D011994:Recombinant Proteins; D018664:Interleukin-12